

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 April 2006 (20.04.2006)

PCT

(10) International Publication Number
WO 2006/040568 A1

(51) International Patent Classification:

C07D 241/40 (2006.01) C07D 409/12 (2006.01)
C07D 403/12 (2006.01) C07D 409/14 (2006.01)
C07D 407/12 (2006.01) A61K 31/498 (2006.01)
C07D 401/12 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/GB2005/003953

(22) International Filing Date: 13 October 2005 (13.10.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/619,373 15 October 2004 (15.10.2004) US

(71) Applicant (for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MK, ML, MN, MR, MW, MX, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG only): **ASTRAZENECA AB** [SE/SE]; S-SE-151 85 Södertälje (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AQUILA, Brian** [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **DAKIN, Les** [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **DEEGAN, Tracey** [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **IOANNIDIS, Stephanos** [GR/US]; AstraZeneca R & D Boston, 35

Gatehouse Drive, Waltham, Massachusetts 02451 (US). **LEE, Stephen** [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **LYNE, Paul** [IE/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **PONTZ, Timothy** [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **SU, Mei** [CN/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-SE-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: QUINOXALINES AS B RAF INHIBITORS



(57) Abstract: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.